About the Company
Celsion is committed to the development of efficient, effective, and targeted therapies for the treatment of cancer and other difficult-to-treat diseases, with the goal of improving patient outcomes in underserved indications. Our extensive, complementary clinical pipeline, stretching from discovery to Phase III, is driven by innovative platform technologies in the areas of chemotherapy, immunotherapy, and DNA- and RNA-based therapy.
NEW YORK, NY / ACCESSWIRE / February 21, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies, is covering Celsion Corp. (CLSN) today, in light of recent...
Celsion to Present Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium
LAWRENCEVILLE, N.J., Jan. 19, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (CLSN) today announced that it will present two posters at the American Society of Clinical Oncology (ASCO) – Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium being held from...
LAWRENCEVILLE, N.J., Jan. 18, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (CLSN), a clinical stage oncology drug development company, today announced that the United States Patent and Trademark Office has granted U.S Utility Patent No. 9,492,385 B2 – Temperature-Sensitive Liposomal...
Celsion Announces Continuing Positive Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients
LAWRENCEVILLE, N.J., Jan. 17, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (CLSN) today announced data from the fourth cohort of patients in its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company’s IL-12 gene-mediated immunotherapy, with the...